146 related articles for article (PubMed ID: 7150347)
21. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
22. Antiestrogenic and antitumor effects of droloxifene in experimental breast carcinoma.
Kawamura I; Mizota T; Mukumoto S; Manda T; Masuda K; Nakamura T; Kubota H; Matsumoto S; Nishigaki F; Shimomura K
Arzneimittelforschung; 1989 Aug; 39(8):889-93. PubMed ID: 2818677
[TBL] [Abstract][Full Text] [Related]
23. CDRI-85/287: studies on competition to estrogen binding sites in the immature rat uterus.
Sreenivasulu S; Dwivedi A; Singh MM; Setty BS; Kamboj VP
Indian J Exp Biol; 1992 Dec; 30(12):1115-7. PubMed ID: 1294475
[TBL] [Abstract][Full Text] [Related]
24. Estrogen and antiestrogen action: studies in reproductive target tissues and tumors.
Katzenellenbogen BS; Tsai TS; Tatee T; Katzenellenbogen JA
Adv Exp Med Biol; 1979; 117():111-32. PubMed ID: 474274
[TBL] [Abstract][Full Text] [Related]
25. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
Sheen YY; Simpson DM; Katzenellenbogen BS
Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
[TBL] [Abstract][Full Text] [Related]
26. Hydroxylated polychlorinated biphenyls (PCBs) as estrogens and antiestrogens: structure-activity relationships.
Connor K; Ramamoorthy K; Moore M; Mustain M; Chen I; Safe S; Zacharewski T; Gillesby B; Joyeux A; Balaguer P
Toxicol Appl Pharmacol; 1997 Jul; 145(1):111-23. PubMed ID: 9221830
[TBL] [Abstract][Full Text] [Related]
27. Physicochemical and genetic evidence for specific antiestrogen binding sites.
Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
[TBL] [Abstract][Full Text] [Related]
28. Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin.
Bouhoute A; Leclercq G
Biochem Biophys Res Commun; 1992 May; 184(3):1432-40. PubMed ID: 1590802
[TBL] [Abstract][Full Text] [Related]
29. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
[TBL] [Abstract][Full Text] [Related]
30. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
31. Speculation on the mechanism of action of triphenylethylene antioestrogens.
van den Koedijk CD; Blankenstein MA; Thijssen JH
Biochem Pharmacol; 1994 Jun; 47(11):1927-37. PubMed ID: 8010979
[No Abstract] [Full Text] [Related]
32. Characterization of a triphenylethylene-antiestrogen-binding site on rat serum low density lipoprotein.
Winneker RC; Guthrie SC; Clark JH
Endocrinology; 1983 May; 112(5):1823-7. PubMed ID: 6832070
[TBL] [Abstract][Full Text] [Related]
33. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
34. [Update on the mechanism of action of synthetic antiestrogens].
Briozzo P; Vignon F; Rochefort H
Ann Endocrinol (Paris); 1989; 50(3):175-80. PubMed ID: 2683972
[TBL] [Abstract][Full Text] [Related]
35. Multiple forms of nuclear estrogen receptor in the immature rat uterus after in vitro exchange with [3H]estradiol or [3H] antiestrogens.
Attardi B
Mol Cell Endocrinol; 1983 Feb; 29(2):159-67. PubMed ID: 6832469
[No Abstract] [Full Text] [Related]
36. Antiestrogens and antiestrogen metabolites: preparation of tritium-labeled (+/-)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxyl]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite.
Tatee T; Carlson KE; Katzenellenbogen JA; Robertson DW; Katzenellenbogen BS
J Med Chem; 1979 Dec; 22(12):1509-17. PubMed ID: 536996
[TBL] [Abstract][Full Text] [Related]
37. Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors.
Harnagea-Theophilus E; Gadd SL; Knight-Trent AH; DeGeorge GL; Miller MR
Toxicol Appl Pharmacol; 1999 Mar; 155(3):273-9. PubMed ID: 10079213
[TBL] [Abstract][Full Text] [Related]
38. Absence of correlation between antiestrogenic activity and binding affinity for the estrogen receptor.
Rochefort H; Garcia M; Borgna JL
Biochem Biophys Res Commun; 1979 May; 88(2):351-7. PubMed ID: 465043
[No Abstract] [Full Text] [Related]
39. Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen.
Katzenellenbogen BS; Ferguson ER
Endocrinology; 1975 Jul; 97(1):1-12. PubMed ID: 166821
[TBL] [Abstract][Full Text] [Related]
40. Estrogen and antiestrogen binding to different forms of the molybdate-stabilized estrogen receptor.
Ruh MF; Brzyski RG; Strange L; Ruh TS
Endocrinology; 1983 Jun; 112(6):2203-5. PubMed ID: 6851947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
